TY - JOUR T1 - Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA4248 VL - 46 IS - suppl 59 SP - PA4248 AU - Chia-Yu Kuo AU - Chih-Jen Yang AU - Ming-Ju Tsai AU - Jen-Yu Hung AU - Jui-Ying Lee AU - Shah-Hwa Chou AU - Ta-Chih Liu AU - Ming-Shyan Huang AU - Inn-Wen Chong Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA4248.abstract N2 - Aims and objectives: Resuming epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) retreatment in patients with stage IV lung adenocarcinoma with acquired resistance to the initial EGFR-TKI is a common treatment strategy. However, the prognostic factor for retreatment with TKI has not been studied yet.Methods: This retrospective study enrolled patients of stage IV lung adenocarcinoma with susceptible EGFR gene mutations diagnosed between June 2009 and October 2013 in two hospitals and followed to September 2014. Baseline characteristics, tumor responses, and progression free survival (PFS) of the first EGFR-TKI were recorded. The PFS of TKI retreatment (PFS2) was taken as the outcome.Results: A total of 72 patients were enrolled. Survival analysis showed significant difference in the PFS2 while classifying the patients according to the smoking history and sex (p = 0.018); female ever smokers had a significantly shorter PFS2 than female never smokers did (p = 0.008). Multivariable Cox regression model developed with backward variable selection method showed that only ever smoker remained an independent poor prognostic factor for PFS2 (HR = 3.8 [95% CI: 1.2–11.7], p = 0.019).Conclusions: Female ever smokers had a significantly poorer PFS on TKI retreatment. Further study is required to understand the underlying mechanisms and to develop a better treatment strategy for these patients. ER -